Trials / Completed
CompletedNCT02407054
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 142 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3023414 | Administered orally |
| DRUG | Enzalutamide | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2015-04-29
- Primary completion
- 2018-09-26
- Completion
- 2020-04-16
- First posted
- 2015-04-02
- Last updated
- 2021-05-11
- Results posted
- 2021-05-11
Locations
36 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02407054. Inclusion in this directory is not an endorsement.